Index

Accelerated approval, 240
Accuracy, 964
ACE (angiotensin-converting enzyme), 5
Acne grading systems, 477
Adaptive designs, 1044
Adaptive dose finding, 142
Adaptive trials, 1018
Adjusting sample size calculations for noncompliance, 1093
Adjuvant therapy, 597
Advanced cancer, 599
Advanced pancreatic adenocarcinoma, 1041
Advantages and limitations of web-based clinical trials, 222
Adverse drug reaction (ADR), 88, 97, 329
classification in humans, 89
Adverse event (AE), 88
common terminology criteria (CTCAE), 289
guidelines for recording, 1029
temporal relationships of, 390
unexpected, 83
Age, 763
Age-related macular degeneration (AMD), 614
AIDS, 27

ALARA (as low as reasonably achievable), 594
Alzheimer disease, 81
Alzheimer’s disease (AD), 81, 149, 668–670, 871, 887, 1140
diagnosis of probable, 670
Animal efficacy rule, 26
Annual reports, 362
Anthrax, 26
Antimetabolites, 3
Area under the curve (AUC), 973
Area under the effect curve (AUEC), 986
Area under the first moment curve (AUMC), 974
Atrial fibrillation, 491
Attrition bias, 515
Bare-metal stents, 406
Bayesian analysis, 840
Bayesian approaches, 146, 267, 268, 1016
Bayesian methods, 998
Belmont report, 1125
Berlin Code of 1900, 903
Best Pharmaceuticals for Children Act (BPCA), 1164
Bias, 1060, 1080
Binary or categorical data, 845
Bioavailability trials, 960
Bioequivalence (BE), 248, 960
Biomarkers, 859, 865, 984
  life cycle, 861
  neuroimaging, 881
  predictive, 889
  to select patient subgroups, 888
  soluble, 886
Biopharmaceutics guidances, 1169
Bioresearch monitoring (BIMO), 58
BLA, 29, 234
Blinding
  indices for assessment of, 949
  trials other than oral drug comparisons, 946
  single, double, and triple blind, 528
  waiving blindness, 947
Boundaries approach, 1037
Breaking code
  in case of emergency, 947
  at end of trial, 950
Brownian motion paradigm, 1050
Carbon dioxide inhalation model, 1219
Carcinosarcoma of female genital, 257
Cardiovascular system, 93
Case report form (CRF), 151, 176, 177
Case-control studies, 315
Caucasian, 762
Causal chain, 1006
Censored endpoints, 847
cGMP quality systems requirements, 38, 40, 42
Chemistry, manufacturing, and controls (CMC), 166
Choice of endpoint, 257
Christmas tree correction, 1038
CIOMS, 1132
Classification of adverse drug reactions (ADRs) in humans, 89
Clinical hold: issues and resolution, 361
Clinical pharmacology guidances, 1170
Clinical risk assessment, 58
Clinical studies necessary for development of new vaccines, 781
Clinical trials
  initiating, 907
  length of, 684
  oral health, statistical issues, 445
  registration, 478
  stimulation, 1011
  using biomarkers, 1217
Clinically relevant outcomes, 984
Cluster randomization, 807
Coefficients of variation, 807
Coercion, 1133
Cognitive tools, 720
CTCAE (common terminology criteria for adverse events), 289
Comparison of two means, 1071
Comparison of two proportions, 1073
Compartmental models, 977
Competence, 1134
Complex response (CR), 287
Concomitant medications, 164
effect of, 391
Conditioned adverse anxiety model, 1220
Confidence intervals, 1055, 1068, 1081
relationship between significant testing and, 1069
Confounding, 1061, 1081
CONSORT (consolidated standards of reporting trials), 940, 1139
Contamination
  of early batches of IPV by simian virus 40 (SV40), 778
  of yellow fever vaccine by hepatitis B, 777
Coronary artery bypass graft, 414
Coronary stent design, 403
Correlation coefficient (r), 1081
Correlative studies, 295
Council for International Organizations and Medical Sciences (CIOMS), 1126
Covariate-adaptive randomization, 799
Covariates, 1081
Cox proportional-hazards method, 1079
C-reactive protein (CRP), 859
Creatinine clearance, 546
CRF, 195
Critical path initiatives, 35
Cross-over designs, 1198
Cross-sectional observational studies, 313
Cutter incident, 778
Cyclo-oxygenase-2 inhibitor, 623
CYP 1A1, 1A2, and 1B1, 752
CYP 1A2, 751
CYP 2C19, 753
CYP 2C9, 753
CYP 2D6, 753
CYP 2E1, 753
CYP 3A4 and 3A5, 753
CYP1A2, 967
CYP2D6, 967
CYP2E1, 961
CYP3A4/5, 967
INDEX 1221

Data
  capture, 153
  cleaning, 208
  electronic capture (EDC), 211
  entry methods, 208
  high-dimensional aspect of, 390
  management study plan, 186
  mining, 343, 1002
  missing, 935
  protection and security issues, 220
  queries, 177
  types, 1062
Data-Monitoring Committee, 293
Data-monitoring safety boards, 904
Data safety and monitoring board (DSMB), 248, 1027, 1050
Declaration of Helsinki, 127, 903, 1121, 1124, 1189
Definition of “Japanese,” 761
Dementia, 712, 716, 719
Demographic characteristics trials, 960
Dental implant clinical trials, 455
Deontological theory, 1120
Diagnostic trials, 280
Dietary factors, 755
Difference in means, 924
Difference in proportions, 926
Differences in means adjusted for baseline data, 926
Disease progression modeling, 1010
Disease-modifying trials, 693
Dose-exposure-response modeling, 1003
Dose-limiting toxicity (DLT), 1015
Dose-range trials, 960
Drug formulation trials, 960
Drug interaction trials, 960
Drug master file (DMF), 239
Drug safety, 865
Drug-eluting stents, 407
Drusen ablation, 616
DSMB, 1041, 1042
DSM-IV criteria for diagnosis of Alzheimer’s disease, 669
E5 guidelines, 747
EDC (electronic data capture), 211
Efficacy, 867, 987
Electrocardiography (EEG), 82
Elixir sulfanilamide, 123
End of phase II (EOP-II), 31, 32
Endocrine system, 100
Endpoint, 1081
Entities involved in clinical trials, 10
Environmental assessment, 1167
Epirubicin in nonresponsive breast cancer, 262
Equivalence trials, 934
Estimating magnitude of treatment difference, 1052
Ethical issues in human pharmacology trials, 956
Ethics committee (HREC), 1108, 904
Ethics, 8
  four golden rules of ethical conduct, 1146
Ethnic factors, 740, 748
Ethnic pharmaceutical safety and efficacy issues, pharmacodynamics, 757
Evidence-based medicine (EBM), 116, 568
Exempted review, 908
Expanded access, 240
Expected effect size, 525
Expeditied review, 910
Exploratory modeling, 1002
Exponential models, 977
Extrinsic factors, 749
Fast-track approval, 366
FDA
  conducting and documenting formal meetings, 357
  consultation with, 356
  FDA-1571, 75
Federal Food, Drug and Cosmetic Act (FDC), 228, 1160
FIAU (fialuridine), 249, 99
Fibonacci sequence, 3
Financial disclosure, 1135
First-in-man (FIM) studies, 247, 1013
First-time-in-man (FTIM), 1191
505(b)(2), 239
Flexible designs, 1202
Fluoxetine bioequivalence study, 970
FOB, 72
Food effect trials, 960
Functional imaging, 883
Gastrointestinal system, 96
Gemcitabine in nasopharyngeal carcinoma, 258, 263
Generic drugs, 238
Genital system and teratology, 103
Genotoxicity, 102
Geometric averages, 991
Geriatric population, 541
GLP regulations in nonclinical investigations, 36
Good tissue practice compliance, 54
Grapefruit, 967
Group sequential designs, 1201
Group sequential testing procedures, 1049
Guillain-Barré Syndrome (GBS) and swine influenza vaccine (1976–1977), 779

Health Insurance Portability and Accountability Act (HIPAA), 300
Healthy normal versus patient population, 763
Hemopoietic system, 100
Hepatic impairment, 550
Hepatic system, 99
hERG, 105, 91
Hierarchy of evidence, 179
HIPAA, 297
Hippocratic Oath, 1123
Historical controls, 817
problems with, 818
Human endotoxemia model, 1219
Human tissue-based products, (HCT/Ps), 54
Human vaccine manufacture, 776
Hypothesis testing, 1065
Hysteresis PKPD models, 988

ICH E8, 1014
ICH E9, 248, 250
ICH
history, 746
implications for non-ICH jurisdictions, 750
ICH M3, 1014
Imaging, 1213
Immunological system, 101
Inactivated influenza vaccine, and Bell’s palsy (2000), 779
Inclusion and exclusion criteria, 283
IND
emergency use of, 27
labeling requirements, 55
review and approval process, 33
Induction therapy, 596
Informed consent forms, 297
Informed consent, 489, 788, 905, 907, 1140

Institutional ethics committee (IEC), 902
Institutional review board (IRB), 26, 28, 46, 47, 49, 79, 231, 482, 644, 902, 904, 1142
registration, 905
review, basic items, 908
Integrated dose-exposure-response modeling, 1008
Intention to treat, 581
Interim analyses, 292
Interventional cardiology, 402
Intrinsic factors, 749
Investigational new drug applications, 358
Investigator
brochure, 76
IND initiated by, 27
responsibilities, 912
selection, 1107
trials initiated by, 27
IRB. See institutional review board
ISO 9001 requirements, 42
James Lind, 118
Japan, traditional practice of medicine in, 742
Joseph Lister, 120
Kaplan-Meier method, 1077
Kefauver-Harris drug amendments, 1161
Kinatica, 978, 982
Linearity, 965
Lithium gamolenate, 1041
Logistic regression model, 987
Log-odds ratio, 1034
Longitudinal models, 1001
Mainland-Gart test, 845
Male and female participants, 763
Masking, 944
Maximally tolerated dose (MTD), 1015
Maximization of research impact on medical treatment, 1147
Maximum concentration (C max), 972
Maximum effect observed (E max), 986
Maximum recommended starting dose (MRSD), 1014
MCP-Mod: unified strategy for dose-finding studies, 1017
Mean, 1063
Measures of neuropsychiatric and behavioral changes, 725
Median approval times, 236
Median, 1063
Medical coding, 210
Medical Dictionary for Regulatory Activities (MedDRA), 210
Medical registers, 317
Meta-analysis, 531
Methotrexate, 3
Microdialysis, 963
Mild cognitive impairment (MCI), 668
Minimization of risk to research participants, 1148
Misrepresentation of estimate of treatment effect and variance, 929
Missing information, 385
Misspecification of rates, 928
Model-based analysis, 836
Monitoring visits, 175
MS
diagnosing in clinical practice, 880
specific features of, 887
Multiple mechanisms, 756
Myocardial infarction, 492

National Formulary, 1160
National Research Act, 903, 1125
NDA review process, 1163
Nervous system, 94
Net present value (NPV), 1182
Neuroimaging biomarkers, 881
Neuropsychiatric symptoms, 676
New drug application (ANDA), 239
Nocebo, 250
Noncompartmental PK parameters, 974
Non-CYP metabolic enzymes, 754
Non-Hodgkin’s lymphoma, 272
Noninferiority trials, 934
NonMEM, 982
Nonparametric analyses, 844
NSAIDs, 97
Nuisance parameters, 1028
Number needed to treat (NNT), 1082
Nuremberg Code, 1149, 126
Nuremberg Military Tribunal, 903
Nuremberg, 1124

Obesity, 559
Office of Human Research Protections (OHRP), 902, 904
Office of Regulatory Affairs (ORA), 229
Oncology studies, 3, 1015
Oncology, 15
Oral rotavirus vaccines (1999), 779
Organ insufficiency trials, 960
Orphan drug, 44, 240
Orphan “same drug” category, 45
Orphan Drug Act, 124
Outcome measures of function, 721
Overrunning analysis, 1044
Over-the-counter (OTC) drugs, 238, 241
Paclitaxel for unresectable hepatocellular carcinoma, 263
Palliative treatment, 600
Pancreatic cancer trial, 1076
Partial response (PR), 287
Pathways modeling, 1008
Patient autonomy of, respect for, 1147
registration, 786
PDUFA, 124, 235
Pediatric drugs, 241
Pediatric initiatives, 1163
Pediatric investigation plans, 651
Pediatric Research Equity Act (PREA), 1164
Pegaptanib sodium, 622
Pentagastrin-induced gastric acid secretion, 1220
Percentile, 1063
Peripheral stents, 423
P-glycoprotein, 1171
Pharmaceutical development in Japan, 743
Pharmacogenetic trials, 960
Pharmacokinetic modeling, 977
Pharmacokinetic-Pharmacodynamic models, 987, 1005
Phase I trial, 233, 247, 249
Phase II trial, 233, 257
efficacy and toxicity in, 265
done of phase II (EOP-II), 31, 32
Phase III trial, 5, 233, 285, 1049
Phase IV trial, 6
Phenylephrine challenge, 1220
Photodynamic therapy, 618
Phototherapy and laser trials, 469
Physiological modeling, 1009
Placebo effect, 288
Placebo-controlled trials, 1131
features, 942
responses, 687
PopKinetics, 982
Population PK data, 981
parameters, 981
Population trials, 961
Postmarketing surveillance, 328, 333
Potency, 987
Power requirement I, 1037
P-Pharm, 982
Precision, 964
Preexisting disease, effect of, 391
Pregnancy trials, 960
Pre-IND meeting, 32
Prescription Drug User Fee Act (PDUFA), 1161
Presymptomatic biomarkers, 881
Prevention trials, 280
Primary endpoint, 1050
Principal investigator, 912
Principlism, 1121
Progression-free survival (PFS), 282
Proof-of-concept studies, 1016
Proof-of-principal/proof-of-concept, 1208
Protect human subjects, 46
Pure Food and Drugs Act, 122
Qualified outcome measures for musculoskeletal disorders, 579
Quality of life (QOL), 9, 570
trials, 280
Quantitative variables, summarizing, 1063
Quinine, 967
Radiation therapy, 620
Radiochemotherapy, 597
Random error, 1061
Randomized clinical trial, 1127
Randomized control trials, 509
Range, 1063
Ranibizumab, 622
Rate constant of the terminal phase (λz), 973
Regional requirements, 748
Regression models, 1000
Regulatory requirements and issues, 252
Renal and urinary system, 100
Renal impairment, 543
Repeated significance testing, 1035
Respiratory system, 96
Response-driven designs, 1044
Review boards, 706
Rheopheresis, 616
Rheumatoid arthritis (RA), 12
Rising dose escalation xtudies, 140
Robustness, 965
Run-in periods, 1090
Safety surveillance of antiretroviral drug, 341
Safety, 250
Sample size, 172, 580, 848, 1090
calculations, 513
re-estimation, 932
Sample-rich trials, 961, 965
SAS, 982
Scientific integrity, 1148
Scopolamine-induced cognitive impairment model, 1219
Screening trials, 280
Seamless designs, 147
Secondary endpoint, 1056
Selectivity, 965
Sensitivity, 931, 965
to ethnic factors, 557, 749
Sepsis, 496
Sequential design, 1040
Sequential probability ratio test (SPRT), 1038
Serious adverse event (SAE), 1111, 1029
Single-stage designs, 260
Single-threshold design (STD), 268
Sire performance, 151
Skin, 101
Special population studies, 536
design features, 538
Special protocol assessments (SPAs), 1165
Special senses, 95
Specificity, 965
Spending function approach, 1036
Stable disease (SD), 287
Standard deviation, 1063
Starting dose, 285
Stenting, 417. See also names of specific stents
Stopping rules, 1040
Stroke, 495, 713
Study close-out activities, 182
Study medication supplies, 164
Subjects, variations among, 390
Surgical device trials, 707
Surrogate endpoint, 878
Surrogate markers, 984
Survival analysis, 1075
Systematic errors, 1060
Terminal half-life, 975
TGN1412, 1014
Therapeutic products directorate (TPD), 1173
Thermal laser photocoagulation, 617
Threshold of toxicological concern (TTC), 103
Time of maximum effect ($t_{\text{E}_{\text{max}}}$), 986
Time to event, 927
Time to progression, 604
Tolerance phenomenon, 985
Torsades de pointes, 91
Total drug clearance, 975
Transpupillary thermotherapy, 618
Trapezoidal rule, 973, 986
Trauma, 713
Treatment IND, 27
Treatment trials, 280
Trial. See also clinical trials
design, 284
size, methods for determining, 923
size, realistic assessment of, 928
surgical device, 707
treatment, 280
Troglitazone, 99
Tuskegee experiment, 1122
$2 \times 2$ crossover design, 248
Two-stage analysis, 837
Two-stage designs, 261
Type I error (significance level), 1165, 1067
Type II error ($1 - \text{power of the test}$), 1165–1166, 1067
Types of adaptive techniques, 138
U.S. Pharmacopeia, 1160
Unequal allocation, 935
Unequal randomization, 806
Unexpected adverse drug experiences, 83
United Kingdom Prescription Event-Monitoring (PEM) program, 337
Utilitarianism, 1120
Vascular dementia (VaD), 668
Waiving blindness, 947
Weight, 764
Weight loss drugs, 1070
WinBUGS, 982
WinNonLin, 978
WinNonMix, 982
Women in clinical trials, 554
and pregnancy, 1143